Search Results
Teprotumumab study finds mixed response rates for active thyroid eye disease
Teprotumumab therapy for active thyroid eye disease demonstrates variable response rates and limited long-term improvement, based on data from a...
Read MoreNew model predicts the course of inactive thyroid eye disease
A predictive model has been developed to identify potential risk factors influencing the progression of inactive thyroid eye disease (TED),...
Read MoreUnique clinical patterns emerge in pediatric thyroid eye disease cases
Pediatric thyroid eye disease (TED) exhibits distinct clinical features compared to adult TED, according to a poster presented at AAO...
Read MoreThree-year follow-up highlights continuing struggles for patients with thyroid eye disease
Amongst patients treated for thyroid eye disease, an early reduction in clinical activity score (CAS), a commonly used measure, did...
Read MoreChoroidal thickening may be an indicator of disease activity in thyroid eye disease
Using swept-source optical coherence tomography (SS-OCT) revealed that subfoveal choroidal thickness (SFCT) is significantly thicker in patients with active thyroid-associated...
Read MoreTeprotumumab therapy shows sustained proptosis improvement in clinical thyroid eye disease
Teprotumumab therapy has shown significant effectiveness in reducing proptosis in patients with clinical thyroid eye disease (TED), with nearly 90%...
Read MoreStudy looks at thyroid eye disease research in a global context
A new analysis shows that thyroid eye disease (TED) research is a globally collaborative effort, drawing expertise from various medical...
Read MoreTeprotumumab shows promise in thyroid eye disease regardless of disease duration
Teprotumumab, an inhibitor of the insulin-like growth factor 1 receptor (IGF-1R), has shown significant promise in treating thyroid eye disease...
Read MoreTeprotumumab shows links to hearing changes in patients with thyroid eye disease
A considerable proportion of patients with thyroid eye disease (TED) treated with teprotumumab experienced hearing loss that met criteria for...
Read MoreTeprotumumab, tocilizumab effective in treating steroid-resistant thyroid eye disease
Teprotumumab and tocilizumab have shown promise as effective alternatives for treating moderate to severe thyroid eye disease (TED) in patients...
Read MoreTeprotumumab shows promise in treating chronic-low clinical activity score thyroid eye disease
Teprotumumab can significantly improve proptosis in patients with chronic thyroid eye disease (TED) who have low levels of inflammation, according...
Read MoreTeprotumumab shows promising results in integrated trials for thyroid eye disease
Results from the European Union (EU) study sites of the clinical trial program evaluating teprotumumab for the treatment of thyroid...
Read MoreCorneal changes may help identify thyroid eye disease earlier
Thyroid eye disease (TED)-related corneal changes may help diagnose TED, especially "silent" TED, earlier, according to a study. This retrospective...
Read More
Contact Info
